跳至主要内容
临床试验/NL-OMON21216
NL-OMON21216招募中不适用

Clinical effectiveness of standard versus pathogen-reduced buffy coat-derived platelet concentrates in plasma in hemato oncological patients.

CaridianBCT Biotechnologies LLC Sanquin Blood supply0 个研究点目标入组 618 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
618

研究概览

简要总结

/A

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Age ≥ 18 years;
  • 2. Expected ≥ 2 platelet transfusion requirements;

排除标准

  • 1. Micro-angiopathic thrombocytopenia (TTP, HUS) and ITP;
  • 2. Bleeding > grade 2 at randomization ( after treatment, the patient can be randomized in the study after 2 or more weeks after the last transfusion that was used to stop the bleeding);

研究者

发起方
CaridianBCT Biotechnologies LLC Sanquin Blood supply

相似试验